Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Feb 7;12(3):e028562.
doi: 10.1161/JAHA.122.028562. Epub 2023 Feb 7.

Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway

Affiliations
Randomized Controlled Trial

Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway

Paul J Wang et al. J Am Heart Assoc. .

Erratum in

Abstract

Background Oral anticoagulation reduces stroke and disability in atrial fibrillation (AF) but is underused. We evaluated the effects of a novel patient-clinician shared decision-making (SDM) tool in reducing oral anticoagulation patient's decisional conflict as compared with usual care. Methods and Results We designed and evaluated a new digital decision aid in a multicenter, randomized, comparative effectiveness trial, ENHANCE-AF (Engaging Patients to Help Achieve Increased Patient Choice and Engagement for AF Stroke Prevention). The digital AF shared decision-making toolkit was developed using patient-centered design with clear health communication principles (eg, meaningful images, limited text). Available in English and Spanish, the toolkit included the following: (1) a brief animated video; (2) interactive questions with answers; (3) a quiz to check on understanding; (4) a worksheet to be used by the patient during the encounter; and (5) an online guide for clinicians. The study population included English or Spanish speakers with nonvalvular AF and a CHA2DS2-VASc stroke score ≥1 for men or ≥2 for women. Participants were randomized in a 1:1 ratio to either usual care or the shared decision-making toolkit. The primary end point was the validated 16-item Decision Conflict Scale at 1 month. Secondary outcomes included Decision Conflict Scale at 6 months and the 10-item Decision Regret Scale at 1 and 6 months as well as a weighted average of Mann-Whitney U-statistics for both the Decision Conflict Scale and the Decision Regret Scale. A total of 1001 participants were enrolled and followed at 5 different sites in the United States between December 18, 2019, and August 17, 2022. The mean patient age was 69±10 years (40% women, 16.9% Black, 4.5% Hispanic, 3.6% Asian), and 50% of participants had CHA2DS2-VASc scores ≥3 (men) or ≥4 (women). The primary end point at 1 month showed a clinically meaningful reduction in decisional conflict: a 7-point difference in median scores between the 2 arms (16.4 versus 9.4; Mann-Whitney U-statistics=0.550; P=0.007). For the secondary end point of 1-month Decision Regret Scale, the difference in median scores between arms was 5 points in the direction of less decisional regret (P=0.078). The treatment effects lessened over time: at 6 months the difference in medians was 4.7 points for Decision Conflict Scale (P=0.060) and 0 points for Decision Regret Scale (P=0.35). Conclusions Implementation of a novel shared decision-making toolkit (afibguide.com; afibguide.com/clinician) achieved significantly lower decisional conflict compared with usual care in patients with AF. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04096781.

Keywords: anticoagulants; anticoagulation; atrial fibrillation; decisional conflict; digital health; shared decision making; stroke.

PubMed Disclaimer

Figures

Figure 1
Figure 1. A, Screenshot of patient web app navigation screen leading to 4 parts of the video: (1) patient video; (2) frequently asked questions; (3) brief quiz; (4) worksheet.
B, Screenshot of opening scene of patient video with animated characters who take the journey to decide about anticoagulation for atrial fibrillation stroke prevention. C, Screenshot of an example of stroke reduction estimate based on atrial fibrillation stroke risk that clinician may use via the clinician web app. D, First page of the worksheet given to the patient to indicate key messages. The second page (not shown) has space for questions that the patient has for the clinician visit. E, QR codes to the patient tool and clinician tool.
Figure 2
Figure 2. Consolidated standards of reporting trials diagram.

Similar articles

Cited by

References

    1. Stroke Prevention in Atrial Fibrillation Study . Final results. Circulation. 1991;84:527–539. - PubMed
    1. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet. 1994;343:687–691. - PubMed
    1. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638–645.e4. doi: 10.1016/j.amjmed.2009.11.025 - DOI - PubMed
    1. Hsu JC, Freeman JV. Underuse of vitamin K antagonist and direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: a contemporary review. Clin Pharmacol Ther. 2018;104:301–310. doi: 10.1002/cpt.1024 - DOI - PubMed
    1. Kunneman M, Branda ME, Hargraves IG, Sivly AL, Lee AT, Gorr H, Burnett B, Suzuki T, Jackson EA, Hess E, et al. Assessment of shared decision‐making for stroke prevention in patients with atrial fibrillation: a randomized clinical trial. JAMA Intern Med. 2020;180:1215–1224. - PMC - PubMed

Publication types

Associated data